All posts by: Michael Zand

About Michael Zand

Athersys tanks as its stem cell therapy flunks a Phase II stroke trial – FierceBiotech

Continue reading

2015-04-17 NEWS

Channel News Asia

Athersys tanks as its stem cell therapy flunks a Phase II stroke trial
FierceBiotech
Athersys’ ($ATHX) in-development stem cell treatment failed to beat placebo in a Phase II trial on stroke patients, demolishing the company’s value as management digs for a positive spin. The company’s treatment, called MultiStem, is meant to reverse
Athersys’ stroke clinical trial yields disappointing resultsCrain’s Cleveland Business

all 17 news articles »

Continue reading

2015-04-17 NEWS

Channel News Asia

Athersys tanks as its stem cell therapy flunks a Phase II stroke trial
FierceBiotech
Athersys’ ($ATHX) in-development stem cell treatment failed to beat placebo in a Phase II trial on stroke patients, demolishing the company’s value as management digs for a positive spin. The company’s treatment, called MultiStem, is meant to reverse
Athersys’ stroke clinical trial yields disappointing resultsCrain’s Cleveland Business

all 17 news articles »